Prevalence of Hepatitis A Virus Infection in a HIV Positive Community
Hepatitis A is acute and usually self – limiting disease, but sometimes it can be dangerous such as in immunosuppressed patients. Purpose of this study is to investigate the prevalence of hepatitis A serology in HIV/AIDS Patients. 247 HIV positive patients from March 2005 to September 2006 were entered in this study. Participants completed questionnaires to elicit demographic, drug and sex risk information, and were tested for hepatitis A. They were all referred to Counseling center for behavioral diseases in Imam Khomeini Hospital. Cases were chosen from volunteers with no history of jaundice or acute hepatitis. Data were analyzed by SPSS version 13 and results were compared between seropositive and seronegative groups using T test and chi square. Statistical significance was accepted at a level of P<0.05. 200 (80.98%) were male and 47(19.02) were female. The mean age was 369.3. 238 (96.3%) of patients were seropositive .One hundred percent and 96% who were born in rural and urban areas were seropositive, respectively. Also, 85.7% and 96.6% who reside in rural and urban areas were seropositive, respectively. Iran is an endemic country for hepatitis A in which most people has asymptomatic infectious during childhood. According to high prevalence of hepatitis A positive serology in HIV/AIDS patients, routine vaccination seems to be unnecessary. But special sub populations like HIV infected infants should be evaluated more precisely and different approaches may be needed for them.
Relevé épidémiologique hebdomadaire. Weekly Epidemiological Record 2000;75:38-42.
Fiore AE, Wasley A, Bell BP; Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendationsof the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-7):1-23.
Hayashi K, Fukuda Y, Nakano I, Katano Y, Nagano K, Yokozaki S, et al. Infection of hepatitis A virus in Japanese haemophiliacs. J Infect 2001;42(1):57-60.
Kahn J. Preventing hepatitis A and hepatitis B virus infections among men who have sex with men. Clin Infect Dis 2002;35(11):1382-7.
Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004;39(5):609-29.
Fainboim H, González J, Fassio E, Martínez A, Otegui L, Eposto M, et al. Prevalence of hepatitis viruses in an antihuman immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat 1999;6(1):53-7.
Ida S, Tachikawa N, Nakajima A, Tachkikawa N, Daikoku M, et al. Influence of human immuno deficiency virus type 1 infection on acute hepatitis A virus infection. Clin infect Dis 2002;34(3):379-85.
Costa-Mattioli M, Allavena C, Poirier AS, Billaudel S, Raffi F, Ferré V. Prolonged hepatitis A infection in an HIV-1 seropositive patient. J Med Virol 2002;68(1):7-11.
Spada E, Genovese D, Tosti ME, Mariano A, Cuccuini M, Proietti L, An outbreak of hepatitis A virus infection with ahigh case-fatality rate among injecting drug users. J Hepatol 2005;43(6):958-64.
González-García JJ, Mahillo B, Hernández S, Pacheco R, Diz S, García P, et al. Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study. Enferm Infecc Microbiol Clin 2005;23(6):340-8.
Gouvêa AF, Moraes-Pinto MI, Machado DM, Carmo FB, Beltrão SC, Cunegundes KS, et al. The prevalence of hepatitis A antibodies in HIV exposed and/or infected children and adolescents. J Pediatr (Rio J) 2005;81(3):205-8.
Ghorbani GA, Alavian SM, Assari S. Seroepidemiology of hepatitis A virus in Iranian soldiers in 2006, Do they need vaccination. Hepatitis Monthly 2007;7(1):7-9.
Moghani Lankarani M, Alavian SM, Manzoori Joybari H. Anti HAV Antibody in HBV Carriers. Govaresh J 2004;9(4):237-41.
Brunet A, Grabar S, Blanche P, Héripret-Fredouille L, Spiridon G, Calboreanu A, et al. Prevalence and risk factors of hepatitis A infection in an HIV-infected French population. Med Mal Infect 2005;35(2):73-81.
Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005;118 Suppl 10A:75S-83S.
Kampe CA, Haubrich R, Frank I, Dubin G, Buscarino C, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus infected patients. J infect Dis 2003;187(8):1327-31.
Mitka M, Rastenyte D, Smith S, Anthony S. Immunogenicity of hepatitis A vaccine in human immunodeficiency virus infected patients. Clin Infect Dis 2004;28(3):346-51.
Loutan M, Gatlin K, Rozy F, et al. Immunogenicity of hepatitis A vaccine in human immunodeficiency virus infected patients. J infect Dis 2004;35(4):226-30.
Shire NJ, Welge JA, Sherman KE. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. Vaccine 2006;24(3):272-9.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.